KALA BIO, Inc. — Director's Dealing 2019

Jan 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2019-01-02

Reporting Person: Chen Hongming (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-02	Stock Option (right to buy)	$5.19	A	150000	Acquired	2029-01-01	Common Stock (150000)	Direct

Footnotes

F1: This option was granted on January 2, 2019 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.